HDAC9 and melanoma: Combination of HDAC inhibitors with PD-1 blockade represents a promising strategy for lung cancer and melanoma treatment by increased expression of multiple T cell chemokines or PD-L1 receptor in cancer cells, macrophages and T cells [28, 29].